Wait‐list mortality of young patients with Biliary atresia: Competing risk analysis of a eurotransplant registry–based cohort

Hubert P. J. van der Doef, Patrick F. van Rheenen, Marieke van Rosmalen, Xavier Rogiers, Henkjan J. Verkade, for pediatric liver transplantation centers of Eurotransplant – 29 January 2018 – Liver transplantation (LT) is the standard treatment for biliary atresia (BA) patients with end‐stage liver disease. The prognosis after LT has steadily improved, but overall prognosis of BA patients is also determined by mortality before LT.

Carcinoembryonic antigen‐related cell adhesion molecule 1 controls IL‐2‐dependent regulatory T‐cell induction in immune‐mediated hepatitis in mice

Andrea Kristina Horst, Claudia Wegscheid, Christoph Schaefers, Birgit Schiller, Katrin Neumann, Sebastian Lunemann, Annika E. Langeneckert, Karl J. Oldhafer, Christina Weiler‐Normann, Karl S. Lang, Bernhard B. Singer, Marcus Altfeld, Linda Diehl, Gisa Tiegs – 29 January 2018 – A dysbalance between effector T cells (Tconv) and regulatory T cells (Tregs) and impaired Treg function can cause autoimmune liver disease. Therefore, it is important to identify molecular mechanisms that control Treg homeostasis.

Direct‐acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease

Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, Larry A. Mole – 29 January 2018 – The impact of sustained virologic response (SVR) on mortality after direct‐acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achieved with interferon‐free DAA treatment on all‐cause mortality in hepatitis C virus–infected patients without advanced liver disease.

Reply

Jennifer C. Lai, Kenneth E. Covinsky, Jennifer L. Dodge, W. John Boscardin, Dorry L. Segev, John P. Roberts, Sandy Feng – 29 January 2018

Subscribe to